Our Mission: Accelerating the discovery, development and global access to life changing radiopharmaceuticals
Our Vision: Transforming lives touched by cancer
In early 2017 Dr. Neil Fleshner, a practicing urologist in Toronto, sent his first prostate cancer patient for an experimental new cancer treatment - Radioligand Therapy. The treatment was not available anywhere in North America – Dr. Fleshner’s patient had to travel to Germany, at significant personal expense, for it to be administered. Wanting to improve patient access to these advancements in cancer care, Dr. Fleshner began thinking about how a team could be assembled to build the infrastructure necessary to bring these innovative therapeutics to more people.
This seed of an idea resulted in the formation of POINT Biopharma.
POINT Biopharma is a clinical-stage global pharmaceutical company focused on the development and commercialization of radioligand therapies for the treatment of cancer. In addition to our exciting pipeline of radioligand molecules for a variety of cancers, we also operate our radiopharmaceutical production facility in Indianapolis, Indiana which is capable of servicing all of North America as well as many global locations.
Dr. McCann has overall responsibility for the day-to-day operations of POINT. Prior to taking on this role, Dr. McCann was CEO of Centre for Probe Development and Commercialization (CPDC) where he led the organization through development and validation of 17 different imaging probe and radiotherapeutic programs, used in national and international clinical trials. Prior to joining CPDC, Dr. McCann was a Scientist in Pharmaceutical Development at GlaxoSmithKline, responsible for developing products across all stages of clinical development.
Dr. McCann has a Ph.D. in biochemistry from McMaster University.
Bill is responsible for all planning, implementation management and operation of all the financial activities of POINT. Previously a senior partner at EY, Bill has over 37 years of professional experience involving a wide range of high-growth companies in the pharmaceutical, manufacturing, and technology sectors, including private and publicly traded Canadian and US NASDAQ listed companies.
Michael is responsible for commercial operations, market strategy and patient focused engagement. Prior to joining, Michael spent 7 years at Sanofi Genzyme Canada leading Commercial Operations, Patient infusions and support programs, Strategy, Finance, and most recently as the Rare Disease Franchise Head responsible for sales and marketing across a broad portfolio of orphan drug and oncology products. While in this role, Michael led teams responsible for physician and patient engagement, market access, and pricing.
Michael is a Chartered accountant and CPA.
Dr. Neil Fleshner graduated with a medical degree from the University of Toronto in 1988. He completed specialty training in urologic surgery and oncology from 1993 to 1996, received a Master’s in Public Health in epidemiology from Columbia University in 1997, and completed his oncology training at Memorial Sloan-Kettering Cancer Center.
Dr. Fleshner is certified in both urology and epidemiology. Dr. Fleshner is also a Professor of Surgery at the University of Toronto. In the past, he has served as the Head of the Division of Urology at the University Health Network, and the Head of Genitourinary Cancer Site group at the Princess Margaret Hospital. He also holds the prestigious Love Chair in prostate cancer prevention at Princess Margaret Hospital.
Ari is responsible for ensuring POINT remains a leader in its industry by operating efficiently and successfully executing on its business strategy. In addition to acting as a representative of the CEO in business strategy and operations, Ari is directly responsible for all corporate affairs, investor relations, communications strategy as well as technology systems at POINT. Previously, Ari was a successful entrepreneur and professional investor for over a decade, having successfully built and exited multiple technology-focused companies.
Todd is responsible for the US manufacturing operations for POINT. Prior to taking on this role, Todd led the construction and operations of a full-scale commercial radiopharmaceutical manufacturing facility at Radiomedix and was previously head of Zevacor’s quality and regulatory affairs team. An industrial engineer, with operations and manufacturing expertise spanning over 25 years, Todd has significant expertise in radiopharmaceutical manufacturing, quality systems and regulatory affairs.
Jessica brings over 15 years of experience developing early and late stage oncology drugs. She joins POINT from Progenics Pharmaceuticals where she served as SVP clinical development advancing their PSMA targeted diagnostic and radiotherapeutic portfolio in prostate cancer and their radiotherapeutic neuroendocrine program which led to the approval of AZEDRA®. Previously, Jessica advanced global immunotherapy programs at the Ludwig Institute for Cancer Research, an orphan drug program at Gentium SpA, now Jazz Pharmaceuticals, and supported the development of a CRO business unit at US Oncology. She has an expertise in study design and execution, has directly led regulatory agency communications and FDA inspections, and the clinical submission of several INDs and NDAs. Jessica started her career in the pharmaceutical industry as a Statistical Programmer and Biostatistician after receiving a Master of Public Health in Epidemiology & Biostatistics at the George Washington University.
As the Exectuive Vice President of Regulatory Affairs. Dr. Herrle brings over 27 years of experience in the pharmaceutical industry in areas such as regulatory affairs and product development. In her previous role, Myra served as Vice Present Regulatory Affairs GlycoMimetics. Prior to GlycoMimetics, she served as Senior Director, Oncology Global Regulatory Affairs at AbbVie. She has a broad experience in Regulatory, Protocol Review, Clinical Development and Biomarkers gained during her tenure at 18 years at Novartis and Glaxo Wellcome/GlaxoSmithKline. Dr. Herrle holds a Ph.D. in Microbiology and Immunology from the University of Oklahoma Health Sciences Center, completed a post-doctoral fellowships in molecular biology NIH and is a licensed pharmacist.
Valerie is responsible for the management of POINT’s early and late-stage clinical development and manufacturing programs. She brings 16 years of experience in the radiopharmaceutical manufacturing space, working with imaging and therapeutic products at Lantheus Medical Imaging (5 years) and the Centre for Probe Development and Commercialization (11 years). In Valerie’s most recent role as the Director of Radiopharmaceutical Development & Supply at CPDC, she was responsible for development, validation and supply of numerous early and late-phase clinical alpha and beta-emitting products. Valerie has a BSc. in Biotechnology from Brock University.
Justyna is responsible for all medical isotope development and operations related to clinical and commercial programs. She brings 11 years of radiopharmaceutical experience from the Centre for Probe Development and Commercialization (CPDC), where she led microbiology and sterility assurance programs, supported the build-out of clinical-stage GMP manufacturing facilities, and managed several internal and Client radiopharmaceutical development programs. Justyna has expertise in working with a variety of medical isotopes, including sourcing, supply chain, development and manufacturing, and application to radiopharmaceutical manufacturing. Justyna has a MSc. in biochemistry from McMaster University.
Robin is responsible for pre-clinical development at POINT. He is an experienced leader in drug discovery and development with broad expertise from early discovery through to first-in-human studies. Previously, Robin was Head of Translational Sciences at Northern Biologics, which focused on developing first-in-class biologics for the treatment of solid tumors. Robin obtained his Ph.D. in biochemistry from McMaster University and completed post-doctoral training at the Hospital for Sick Children in cancer biology.